Experience
GlaxoSmithKline
Apotex Corp.
Finnegan represented GlaxoSmithKline (“GSK”) in various patent infringement litigations protecting GSK’s Paxil® antidepressant drug against many generic drug manufacturers that filed ANDA suits seeking to sell generic versions of the drug. Finnegan worked with GSK’s antitrust counsel to settle multiple litigations and minimize their antitrust risk. After one of those settlements, the generic drug manufacturer’s API supplier brought an antitrust suit challenging the settlement. Finnegan worked with GSK’s antitrust counsel to successfully defeat the antitrust claim in a motion to dismiss strongly upholding the right of patent owners to settle ANDA litigations. Finnegan also worked with GSK’s antitrust counsel in defending related class action antitrust suits brought by other litigants based on patent infringement litigations.
GlaxoSmithKline v. Apotex Corp., 1:02-mc-00097, M.D.N.C., Judge Surrick
Finnegan client Elan protected against antitrust claims based on ANDA settlement
Elan Corporation PLC
Philips protected against antitrust and misuse charges in DVD and CD infringement litigation
U.S. Philips Corp.
Philips protected against antitrust and misuse charges in DVD and CD infringement litigation
U.S. Philips Corp.
Winbond Electronics protected in DRAM antitrust price-fixing cases
Windbond Electronics Corporation
MRIS protected against collusion and monopolization claims
Metropolitan Regional Information Systems, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.